Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01394939 · ClinicalTrials.gov registry record · Phase 1
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Phase 1 study of Colorectal Carcinoma and CRC, sponsored by Jennerex Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 11
- Study locations
NCT01394939 is a Phase 1 study of Colorectal Carcinoma and CRC that has completed, run by Jennerex Biotherapeutics. The registered enrollment target is 52 participants, below the 1,095-participant average among 53 other Colorectal Carcinoma trials with a reported enrollment target (95% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT01394939, a Phase 1 study of Colorectal Carcinoma and CRC, has completed, sponsored by Jennerex Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JX-594 (Pexa-Vec) administered intravenously either alone or in combination with Irinotecan in colorectal carcinoma patients who are refractory to or intolerant to standard therapy.
Conditions Studied
Interventions
- DRUG Irinotecan
- BIOLOGICAL JX-594
Study Locations (11)
Other
- Hôpital Saint Antoine - Paris
- Hôpital Hautepierre - Strasbourg
- Institut Claudius Regaud - Toulouse
Ohio
- Gabrail Cancer Center - Canton
- The Ohio State University - Columbus
Ontario
- Juravinski Cancer Centre - Hamilton
- Ottawa Hospital and Research Institute (OHRI) - Ottawa
Arizona
- Mayo Clinic - Scottsdale
California
- UCSD Moores Cancer Center - La Jolla
Montana
- Billings Clinic Cancer Center - Billings
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01394939
The ClinicalTrials.gov registry entry for NCT01394939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,095-participant average among 53 other Colorectal Carcinoma trials with a reported enrollment target (95% lower). The listed sponsor is Jennerex Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Irinotecan is the first listed.
NCT01394939 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Other, Ohio, Ontario.
Frequently Asked Questions
What is clinical trial NCT01394939 about?
NCT01394939 is a clinical study titled "Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma". The purpose of this study is to evaluate the safety, tolerability, and efficacy of JX-594 (Pexa-Vec) administered intravenously either alone or in combination with Irinotecan in colorectal carcinoma patients who are refractory to or intolerant to standard therapy.
What is the current status of trial NCT01394939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2012-01. Estimated completion is 2015-10.
What conditions does trial NCT01394939 study?
This clinical trial studies the following conditions: Colorectal Carcinoma, CRC.
What interventions are being tested in trial NCT01394939?
The interventions under investigation include: Irinotecan (DRUG), JX-594 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01394939?
This trial is sponsored by Jennerex Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01394939 being conducted?
This trial has 11 study locations across Arizona, California, Montana, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
RECRUITING · Phase 1
-
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
RECRUITING · Phase 1
-
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.